topper's finally got some new material, page-55

re: sirtex medical adding more centers You are not keeping up with the website. The company has added two more centers this week and a total of 11 since the last excellent earnings report when the revenues wer up 130% and in the US up 97% where it gets 14,000 USD per treatment with the average patient receiving 1.7 treatments which is $24,000 in revenues on average per patient. The company has added 36 centers in the US since last December. The trend is clearly up alot. The earnings driver is the training of more oncologists and the combination therapy of Sir Spheres with Irinotecan and Oxaliplatin which are newer generation chemotherapy drugs from Sanofi and Pfizer respecticely. After talking to the company they believe that they have only scratched the surface for eligible patients as the US market alone has about 200,000- 250,000 eligible patients per year. At only 10% penetrance or 25,000 patientsx $24,000 per patient this is 600 million in USD in revenues a coouple of years out. At 25% net margin this is 150 million/55 million shares out = $ 2.72 a share in earnings. This does not consider growth or sales outside the US. Also it does not consider new indications for the product and this is already happening with recent positive breast trials with Sir Spheres and chemo. AT $1.95 a share it is easy to see the good prospects for the sp and the reason Cephalon had when it bid $4.85 a share 2 years ago. I feel Dr Gray has got the company revved up for good growth so that he will be in the drivers seat to eventually be bought out by a big pharma co like Pfizer or Sanofi. This is my opinion, as I am in the industry.Do your own homework.